Join Arrowhead Pharmaceuticals for Part IV of its 2024 Summer Series of R&D Webinars, featuring Prof. Carel le Roux, Chair of Metabolic Medicine at University College Dublin. Arrowhead management will provide updates on two preclinical programs addressing obesity and metabolic diseases, including ARO-INHBE, an investigational RNAi-based medicine that targets hepatic expression of the INHBE gene, as well as a new adipose target.

A live question and answer session will follow the formal presentation.